The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Justin Taylor named recipient of Stanley J. Glaser Award to reseach potential colorectal cancer treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Justin Taylor, a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has received a Stanley J. Glaser Foundation Research Award to continue the research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Fred Hutch announces eight recipients of 2025 Dr. Eddie Méndez Scholar Award

2025 Dr. Eddie Méndez Scholar Award Recipients, top row left to right: Caitlin Cornell, PhD, Elizabeth Kaweesa, PhD, Leandro Fernández-García, PhD, Almudena Chaves Pérez, PhD. Bottom row left to right: Luis Cedeño-Rosario, PhD, Nicole Halmai, PhD, Megan E. Meuser, PhD, Sarah Elisabeth Pierce, PhD.  Fred Hutch Cancer Center has announced eight recipients of the 2025 Dr. Eddie Méndez Scholar Award. 
Editorial

The Cancer Letter receives nine journalism, design awards

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

By Katie Goldberg
Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account